Waverly Advisors LLC Increases Stock Holdings in DexCom, Inc. $DXCM

Waverly Advisors LLC increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 18.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 64,920 shares of the medical device company’s stock after purchasing an additional 10,187 shares during the period. Waverly Advisors LLC’s holdings in DexCom were worth $4,372,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Brighton Jones LLC raised its position in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after buying an additional 11,946 shares during the period. Integrated Wealth Concepts LLC grew its position in DexCom by 6.3% in the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares during the period. Empowered Funds LLC grew its position in DexCom by 5.4% in the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after acquiring an additional 436 shares during the period. Focus Partners Wealth increased its stake in DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after acquiring an additional 841 shares during the last quarter. Finally, NewEdge Advisors LLC increased its stake in DexCom by 1.4% during the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after acquiring an additional 258 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on DXCM shares. Weiss Ratings raised DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Wall Street Zen raised DexCom from a “hold” rating to a “buy” rating in a research report on Sunday, September 6th. Benchmark boosted their price objective on shares of DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a research report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 target price on the stock. Finally, TD Cowen reaffirmed a “buy” rating on shares of DexCom in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

Insider Transactions at DexCom

In other news, EVP Michael Brown sold 1,700 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the sale, the executive vice president owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the transaction, the director directly owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. The trade was a 7.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 65,777 shares of company stock valued at $4,950,714. 0.28% of the stock is owned by insiders.

DexCom Stock Up 0.8%

NASDAQ:DXCM opened at $84.51 on Friday. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59. The stock’s fifty day moving average is $82.51 and its two-hundred day moving average is $72.73. The stock has a market capitalization of $31.89 billion, a price-to-earnings ratio of 33.40, a price-to-earnings-growth ratio of 1.41 and a beta of 1.42. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company’s revenue was up 13.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.48 earnings per share. Research analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current year.

DexCom Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.